BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36686485)

  • 1. Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer.
    Lin J; Cai Y; Wang Z; Ma Y; Pan J; Liu Y; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():1005916. PubMed ID: 36686485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 3. A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.
    Huang J; Liu D; Li J; Xu J; Dong S; Zhang H
    Ann Med; 2023; 55(2):2260387. PubMed ID: 37729607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
    Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer.
    Liu P; Wang W; Wang F; Fan J; Guo J; Wu T; Lu D; Zhou Q; Liu Z; Wang Y; Shang Z; Chan FL; Yang W; Li X; Zhao SC; Zheng Q; Wang F; Wu D
    J Transl Med; 2023 Jan; 21(1):40. PubMed ID: 36681849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
    Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
    Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
    Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
    Front Oncol; 2020; 10():571308. PubMed ID: 33598420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
    Puca L; Vlachostergios PJ; Beltran H
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
    Franceschini GM; Quaini O; Mizuno K; Orlando F; Ciani Y; Ku SY; Sigouros M; Rothmann E; Alonso A; Benelli M; Nardella C; Auh J; Freeman D; Hanratty B; Adil M; Elemento O; Tagawa ST; Feng FY; Caffo O; Buttigliero C; Basso U; Nelson PS; Corey E; Haffner MC; Attard G; Aparicio A; Demichelis F; Beltran H
    Cancer Discov; 2024 Mar; 14(3):424-445. PubMed ID: 38197680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression.
    Zhang T; Zhao F; Lin Y; Liu M; Zhou H; Cui F; Jin Y; Chen L; Sheng X
    Theranostics; 2024; 14(3):1065-1080. PubMed ID: 38250042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
    Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
    Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
    Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
    J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer.
    Zhang Q; Zhang P; Zhao Z; Wang J; Zhang H
    PeerJ; 2023; 11():e15013. PubMed ID: 37070095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
    He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
    Lee AR; Che N; Lovnicki JM; Dong X
    Front Oncol; 2018; 8():93. PubMed ID: 29666783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.